Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software that helps with the early diagnosis of cardiac amyloidosis, enabling timely ...

Fat cells from patients who had lost weight after bariatric surgery, as well as from animals who had gained and then lost weight, were transcriptionally distinct from cells that had not experienced ...

Transposon Therapeutics Inc. has acquired a portfolio of novel nucleoside analogues from Primefour Therapeutics Inc. for the targeted treatment of pancreatic cancer, certain other solid tumors and ...

Researchers from Xencor Inc. described the preclinical characterization of XmAb-808.

Urocortin-2 (UCN2) is a selective corticotropin-releasing factor CRF2 receptor (CRFR2) agonist, which has been previously shown to reduce fat mass while promoting muscle hypertrophy. Hanmi ...

Former U.S. FDA Commissioner Margaret Hamburg has added her voice to concerns that the incoming Trump administration’s pledge to slim down federal agencies will damage public health. “These are ...

Enanta Pharmaceuticals Inc. has released preclinical pharmacokinetics (PK) data for EDP-514, a potent and selective class II core assembly modulator in phase I development for the oral treatment of ...

The U.S. FDA approved 15 drugs in October, marking a decline from 24 in September and 22 in August. Despite the drop, the 2024 monthly average stands at about 19 approvals, exceeding last year’s ...

Chiome Bioscience Inc. and Asahi Kasei Pharma Corp. have entered into an exclusive license agreement to develop and commercialize Chiome’s humanized anti-CX3CR1 antibody, PFKR, currently in the ...

Autoimmunity Biosolutions has closed a seed financing to support its work advancing a next-generation, immuno-corrective therapy for autoimmune diseases. The company’s approach targets a branch of the ...

Startup company Pep2tango Therapeutics Inc., unveiled with backing by Versant Ventures, is advancing unimolecular multireceptor peptide agonists that target GLP-1, GIP, amylin and calcitonin receptors ...

Therabene Inc. has released promising preclinical results for two new novel molecules targeting aggressive cancers.